Did you mean 40503 39 0?
Displaying drugs 826 - 850 of 1525 in total
Hypericin
Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.
Investigational
Matched Iupac: … 5,7,11,18,22,24-hexahydroxy-13,16-dimethyloctacyclo[13.11.1.1^{2,10}.0^{3,8}.0^{4,25}.0^{19,27}.0^{21,26 ... }.0^{14,28}]octacosa-1(27),2(28),3,5,7,10,12,14,16,18,21,23,25-tridecaene-9,20-dione …
VXM01
Investigational
VB2-011
VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).
Investigational
CZEN 002
CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses. It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. This organism can invade tissues and produce fatal...
Investigational
CLX-0921
CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma. It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to...
Investigational
AZD-0328
AZD0328 has been used in trials studying the treatment and basic science of Schizophrenia and Alzheimer's Disease.
Investigational
GDC-0810
ARN-810 has been used in trials studying the basic science and treatment of Breast Cancer.
Investigational
GDC-0917
CUDC-427 has been used in trials studying the treatment of LYMPHOMA and Solid Cancers.
Investigational
CYNK-001
CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Investigational
ETBX-011
ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
Investigational
ETBX-021
Investigational
ETBX-061
Investigational
AVR-RD-01
AVR-RD-01 is an investigational ex vivo lentiviral gene therapy developed by AVROBIO Inc. It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence. AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968]
Investigational
ABSK-012
Investigational
PLG-0206
PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational
BRG01
BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.
Investigational
OSSM-007
OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells.
Investigational
AVR-RD-05
AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced ex vivo with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).
Investigational
ANEB-001
ANEB-001 is under investigation in clinical trial NCT05282797 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test).
Investigational
Latozinemab
Investigational
Zalsenertant tetraxetan lutetium Lu-177
Investigational
Displaying drugs 826 - 850 of 1525 in total